The PCSK9 inhibitor evolocumab reduced the risk of a first major cardiovascular event in patients with diabetes without known significant atherosclerosis, according to a prespecified subgroup analysis ...
kholodilinivan / CVSystem Public Notifications You must be signed in to change notification settings Fork 1 Star 5 Code Projects Security Insights Code Issues Pull requests Actions Projects Files main ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results